Insulet Corporation Company Profile (NASDAQ:PODD)

Insulet Corporation trades on the NASDAQ under the ticker symbol "PODD."

Insulet Corporation (NASDAQ:PODD) released its earnings results on Thursday, August, 3rd. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $110 million for the quarter, compared to analyst estimates of $106.23 million. Insulet Corporation had a negative return on equity of 46.74% and a negative net margin of 7.30%. Insulet Corporation's revenue was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.08) earnings per share. View Insulet Corporation's Earnings History.

Insulet Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Insulet Corporation.

15 brokers have issued 1-year price targets for Insulet Corporation's shares. Their predictions range from $38.00 to $65.00. On average, they anticipate Insulet Corporation's stock price to reach $51.08 in the next twelve months. View Analyst Ratings for Insulet Corporation.

Here are some recent quotes from research analysts about Insulet Corporation stock:

• 1. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
• 2. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (7/20/2017)
• 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
• 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)

Some companies that are related to Insulet Corporation include Ionis Pharmaceuticals (IONS), TESARO (TSRO), Henry Schein (HSIC), Bioverativ (BIVV), DexCom (DXCM), Icon Plc (ICLR), bluebird bio (BLUE), Dr. Reddy's Laboratories Ltd (RDY), Envision Healthcare Corporation (EVHC), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), Neurocrine Biosciences (NBIX), athenahealth (ATHN), Valeant Pharmaceuticals International (VRX), Hill-Rom Holdings (HRC) and Juno Therapeutics (JUNO).

Insulet Corporation's management team includes the folowing people:

• Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer
• Shacey Petrovic, President, Chief Operating Officer
• Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer
• Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development
• David Colleran J.D., Senior Vice President, General Counsel, Secretary
• Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering
• Charles Alpuche, Senior Vice President - Global Manufacturing and Operations
• Michael Spears, Senior Vice President - Quality and Regulatory Affairs
• Bret Christensen, Chief Commercial Officer
• Jessica Hopfield Ph.D., Lead Independent Director

Insulet Corporation's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Capital Research Global Investors (10.13%), Vanguard Group Inc. (8.04%), BlackRock Inc. (6.90%), Frontier Capital Management Co. LLC (3.12%) and Fred Alger Management Inc. (2.18%). Company insiders that own Insulet Corporation stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet Corporation.

Insulet Corporation's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, BlackRock Inc., Rainier Investment Management LLC, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., JPMorgan Chase & Co., Federated Investors Inc. PA and Fiera Capital Corp. Company insiders that have sold Insulet Corporation stock in the last year include David A Lemoine, Joseph S Zakrzewski and Regina O Sommer. View Insider Buying and Selling for Insulet Corporation.

Insulet Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Lord Abbett & CO. LLC, Renaissance Technologies LLC, Marshall Wace North America L.P., Capital Research Global Investors, Vanguard Group Inc., State Street Corp and Delta Lloyd Asset Management N.V.. Company insiders that have bought Insulet Corporation stock in the last two years include Bradley A Thomas, Charles Alpuche, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet Corporation.

Shares of Insulet Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Insulet Corporation stock can currently be purchased for approximately $57.83.